MedTrace Logo

Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

NCT00524030 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2021-01-20

Study results available
· View outcomes & findings →

Summary

This study will determine the safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy subjects for the treatment of partial seizures. The duration of the trial is about 6 months.

Conditions

  • Epilepsies, Partial

Interventions

DRUG

pregabalin 600 mg/day

pregabalin 600 mg/day (300mg BID), duration is 20 weeks.

DRUG

pregabalin 150 mg/day

pregabalin 150 mg/day (75mg BID), duration is 20 weeks.

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2011-04-30
Completion
2011-06-30

Countries

  • United States
  • Czechia
  • Hong Kong
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00524030 on ClinicalTrials.gov